Sunbird Bio has merged with Glympse Bio to fast-track the development of protein-based diagnostic technologies.
Set to operate as Sunbird Bio, Inc., the newly merged entity will have its US headquarters in Cambridge, Massachusetts, and its operational headquarters in Singapore.
With a pipeline of diagnostic tests, the combined company will focus on clinical-stage platform development with demonstrated potential for improving patient care in Alzheimer’s and other neurological disorders.
The diagnostic tests are based on the APEX and Glympse technology platforms.
These platforms can identify the properties and activity of circulating proteins to provide insights to researchers and clinicians, which current tests cannot provide.
APEX is a proprietary diagnostic system that detects aggregated amyloid-β in circulation using a blood sample.
It has shown its capability to accurately identify the aggregation of this peptide, a crucial factor in the pathogenesis of Alzheimer's disease.
The Glympse diagnostic platform is said to be the first to demonstrate its ability to measure and analyse protease activity within the bloodstream.
This capability enables prompt and precise detection, enhancing well-informed strategies for treatment planning and monitoring.
In partnership with biopharma companies and researchers, Sunbird Bio plans to introduce its complete range of diagnostic tests for Alzheimer's and other neurological conditions.
Additionally, they are engaged in advancing early-stage cancer diagnostics using the Glympse platform.
Sunbird Bio executive chair and CEO John McDonough said: “The APEX and Glympse platforms have the potential to dramatically improve standards of care for many diseases by overcoming the inaccessibility, invasiveness and lack of reliability associated with current diagnostic approaches that limit their usefulness in drug development, disease detection, disease monitoring, and personalised treatment selection.”
The companies have not disclosed the financial details related to the merger.
